Seebri Breezhaler glycopyrronium bromide: Phase III data

The double-blind Phase III GEM 1 and 2 trials in patients with moderate to severe COPD showed that twice-daily NVA237 met the primary endpoint in each trial of improving FEV1 AUC from 0-12 hours at we...